Last reviewed · How we verify
Colchicine 0.25 MG
At a glance
| Generic name | Colchicine 0.25 MG |
|---|---|
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
- Different Doses of Colchicine on hsCRP (PHASE4)
- Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (PHASE3)
- Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease (PHASE2)
- Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: